Fang Liu

Dr. Fang Liu


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
FQFei Qi
Fei Qi
FLFang Liu
Fang Liu
LGLing Gao
Ling Gao
Vitiligo is a multifactorial reversible skin disorder characterized by distinct white patches that result from melanocyte destruction. Activated CXCR3+ CD8+ T cells promote melanocyte detachment and apoptosis through interferon-gamma (IFN-γ secretion and chemokines secreted by keratinocytes through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT)-1 signaling pathway results in further recruitment of CXCR3+ CD8+ T cells and the formation of a positive-feedback loop. JAK inhibitors target the JAK/STAT pathway and are now approved to treat many immune-related diseases. In the treatment of vitiligo, JAK inhibitors, including ruxolitinib, baricitinib, and tofacitinib, are effective, supporting the implication of the IFN-γ-chemokine signaling axis in the pathogenesis of vitiligo. However, more studies are required to determine the ideal dosage of JAK inhibitors for the treatment of vitiligo, and to identify other inflammatory pathways that may be implicated in the pathogenesis of this condition.

1 April 2022 in Dose-Response
Verified
Journal Article
Open access
JDJie Dong
Jie Dong
XHXuan Huang
Xuan Huang
LMLi-Ping Ma
Li-Ping Ma
FQFei Qi
Fei Qi
SWSi-Nian Wang
Si-Nian Wang
FLFang Liu
Fang Liu
Objective: To evaluate the clinical efficacy and safety of baricitinib, a Janus kinase (JAK) inhibitor, in treating patient with progressing vitiligo, and to further explore the regulation of baricitinib on melanocytes (MCs) in vitro. Methods: Four patients with progressing vitiligo were treated with oral baricitinib for a total of 12 weeks. MCs were cultured in vitro and irradiated by high-dose ultraviolet B (UVB, 150mJ/cm2) to make an MC damaged model (MC-Ds). Baricitinib was added at a final concentration of 25 μM. Dopamine staining and NaOH method were used to measure the tyrosinase activity and melanin level, respectively, real-time quantitative polymerase chain reaction (RT-qPCR) was used to measure the mRNA levels of tyrosinase (TYR), tyrosinase-related protein-1 (TRP-1). Results: Significant re-pigmentation was observed in the week 12 without obvious side effects. Depigmentation occurred in 2 patients at the 3-month follow-up. Laboratory research found that higher doses of UVB irradiation (150mJ/cm2) could decrease melanin content of MCs, baricitinib (25 μM) could significantly promote tyrosinase activity, melanin content, and TYR, TRP-1 gene expression of MC-Ds. Conclusion: Our preliminary study showed that baricitinib was effective and safe in treating progressing vitiligo. Baricitinib could promote tyrosinase activity, melanin content and TYR, TRP1 gene expression of MC-Ds in vitro.

1 March 2022 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
JZJingya Zhang
Jingya Zhang
FQFei Qi
Fei Qi
JDJie Dong
Jie Dong
YTYaqi Tan
Yaqi Tan
LGLing Gao
Ling Gao
FLFang Liu
Fang Liu
There are four JAK subtypes: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). Small molecule Janus tyrosine kinase (JAK) inhibitors can inhibit a variety of pro-inflammatory cytokines. Baricitinib is the first generation of JAK1/2 inhibitor targeting the ATPase of JAK, which blocks the intracellular transmission of cytokines through JAK-STATs. Thus far, it has been approved for the treatment of rheumatoid arthritis (RA); however, an increasing number of studies have suggested that baricitinib can be used to treat dermatological diseases, such as atopic dermatitis (AD), psoriasis, vitiligo, and alopecia areata. Baricitinib can be a new choice for the treatment of dermatological diseases, which cannot be treated with conventional drugs. We reviewed the application, efficacy, side effects, precautions, limitations and prospect of baricitinib in atopic dermatitis, psoriasis, vitiligo and alopecia areata (AA) in recent 5 years including clinical trials and case reports. Among them, the application in the field of alopecia areata is the most encouraging, and we reviewed the mechanism in detail.

23 November 2020 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
XWXiangguo Wang
Xiangguo Wang
QLQianru Li
Qianru Li
TXTongtong Xie
Tongtong Xie
MYMengyi Yuan
Mengyi Yuan
XSXihui Sheng
Xihui Sheng
HNHemin Ni
Hemin Ni

28 July 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
XSXiangxi Su
Xiangxi Su
FLFang Liu
Fang Liu
Vitiligo is a chronic autoimmune disorder in which melanocyte−specific CD8+ T cells destroy pigment−forming cells, producing persistent depigmented macules. Recurrence after treatment implicates tissue−resident memory T (TRM) cells that are maintained by interleukin−15 (IL−15) signaling. Here we review current insights into TRM−cell biology, summarize experimental and emerging clinical data targeting the IL−15/CD122 axis—including the ongoing Phase 2a AMG 714 trial—and discuss combination strategies with approved topical Janus kinase inhibitors such as ruxolitinib cream. Disrupting IL−15 may offer durable repigmentation with minimal systemic immunosuppression.

1 July 2024 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
XHXinlyu Huang
Xinlyu Huang
PZPengxiang Zhao
Pengxiang Zhao
GZGongjie Zhang
Gongjie Zhang
XSXiangxi Su
Xiangxi Su
HLHanlin Li
Hanlin Li
FLFang Liu
Fang Liu
Purpose: Alopecia significantly affects the appearance and psychology of patients, and pharmacological therapies and hair transplantation are the main treatments for alopecia, but both have limitations. This review aimed to summarize the non-pharmacological therapies that promote hair growth and regeneration. Patients and Methods: This is a non-systematic review. Multiple databases was searched with relevant data published between 1997 and 2024. Searching and screening followed the PRISMA guidelines. Results: Novel therapeutic modalities, such as gas molecules, platelet-rich plasma, laser, and microneedling, can change the microenvironment of hair follicles, activate hair follicle stem cells, and promote hair growth and regeneration. Conclusion: This paper reviews research on the application of non-pharmacological therapies in alopecia treatment and hair regeneration, with a view to providing an important basis for future research on alopecia treatment and the postoperative treatment of patients after hair transplantation.